Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury.

NCT ID: NCT06617182

Last Updated: 2024-10-01

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 150 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-09-30
• Study Completion Date: 2026-10-01

Brief Summary

At present, there is still a lack of standard and effective treatment strategies and procedures for radiation intestinal injury. Studies have shown that thalidomide can effectively treat refractory gastrointestinal bleeding caused by vascular malformation. Therefore, The investigators designed a single-center, open-label, randomized controlled study to evaluate the efficacy and safety of thalidomide combined with glutamine in the treatment of radiation intestinal injury.

Detailed Description

Screening: This phase will not last longer than one week, and the subject will be assessed for eligibility after signing the informed consent form.

Treatment: Subjects were randomly assigned to three different treatment groups for 8 weeks.

Follow-up: The subjects' defecation status was recorded every day during treatment, telephone follow-up was conducted every two weeks, and laboratory indicators (including blood routine, stool routine, etc.) were tested every four weeks. The test was terminated one week after treatment and the improvement of subjects' stool blood was assessed.

Conditions

Radiation Enteritis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

The thalidomide group

Patients in the thalidomide group will receive oral thalidomide at a dosage of 100 mg one time daily for 8 weeks.

Group Type: EXPERIMENTAL

Thalidomide

Intervention Type: DRUG

Patients in thalidomide group took thalidomide orally at a dose of 100mg once a day for 8 weeks.

The glutamine group

Patients in the glutamine group were given two enteric-soluble capsules of compound glutamine three times a day for 8 weeks.

Group Type: EXPERIMENTAL

Glutamine

Intervention Type: DRUG

In the glutamine group, two capsules of glutamine were taken orally 3 times a day for 8 weeks.

The thalidomide combined with glutamine group

Patients in the thalidomide combined with glutamine group will receive oral thalidomide at a dosage of 100 mg one time daily and two enteric-soluble capsules of compound glutamine three times a day for 8 weeks.

Group Type: EXPERIMENTAL

Thalidomide+Glutamine

Intervention Type: DRUG

Patients in thalidomide combined with glutamine group took thalidomide orally at a dose of 100mg once a day and two capsules of glutamine were taken orally 3 times a day for 8 weeks.

Interventions

Thalidomide

Patients in thalidomide group took thalidomide orally at a dose of 100mg once a day for 8 weeks.

Intervention Type: DRUG

Glutamine

In the glutamine group, two capsules of glutamine were taken orally 3 times a day for 8 weeks.

Intervention Type: DRUG

Thalidomide+Glutamine

Patients in thalidomide combined with glutamine group took thalidomide orally at a dose of 100mg once a day and two capsules of glutamine were taken orally 3 times a day for 8 weeks.

Intervention Type: DRUG

Other Intervention Names

Compound glutamine enteric-coated capsules

Eligibility Criteria

Inclusion Criteria

• Age 18-80 years old, gender is not limited;
• Patients with hematochezia symptoms of chronic radiation intestinal injury: Due to the lack of diagnostic gold standard for radiation intestinal injury, a comprehensive analysis of clinical, endoscopic, imaging and histopathological findings was mainly performed to make the diagnosis of radiation intestinal injury on the basis of excluding infectious and other non-infectious intestinal injuries. Exposure to radioactive sources is a necessary factor in the diagnosis of radiation intestinal injury, and tumor activity or recurrence should be excluded.
• The proportion of dominant defecation bleeding in total defecation times in the week before treatment is not less than 20%;
• ECOG score: 0-2.

Exclusion Criteria

• Patients with hemodynamic instability;
• Patients with obvious liver and kidney function injury: bilirubin, aminotransferase (ALT, AST) exceeded the upper limit of normal by 2 times; eGFR<60ml/min or dialysis patients;
• Patients allergic to thalidomide or glutamine;
• Patients whose primary disease was gastrointestinal malignancy;
• Patients currently suffering from serious or uncontrolled underlying diseases of the blood, digestive tract, metabolism, endocrine, lung, heart, nervous system, mental system, etc.;
• Female patients during pregnancy and breastfeeding (including patients with reproductive needs);
• Patients infected with HIV;
• Patients who cannot cooperate with regular follow-up and review of laboratory indicators;
• any other circumstances which, in the opinion of the investigator, would render the subject unfit for study inclusion.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Yongquan Shi

OTHER

Sponsor Role: lead

Responsible Party

Yongquan Shi

Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Central Contacts

Yongquan Shi

Role: CONTACT

shiyquan@fmmu.edu.cn

0086 + 02984771515

Other Identifiers

KY20242229-F-1

Identifier Type: -

Identifier Source: org_study_id